- Home
- KPTI vs PMVP Comparison
KPTI vs PMVP Comparison
Compare KPTI & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- PMVP
- Stock Information
- Founded
- KPTI 2008
- PMVP 2013
- Country
- KPTI United States
- PMVP United States
- Employees
- KPTI N/A
- PMVP N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- KPTI Health Care
- PMVP Health Care
- Exchange
- KPTI Nasdaq
- PMVP Nasdaq
- Market Cap
- KPTI 66.7M
- PMVP 71.9M
- IPO Year
- KPTI 2013
- PMVP 2020
- Fundamental
- Price
- KPTI $7.53
- PMVP $1.26
- Analyst Decision
- KPTI Strong Buy
- PMVP Strong Buy
- Analyst Count
- KPTI 5
- PMVP 3
- Target Price
- KPTI $61.00
- PMVP $5.33
- AVG Volume (30 Days)
- KPTI 144.0K
- PMVP 136.3K
- Earning Date
- KPTI 05-07-2025
- PMVP 03-03-2025
- Dividend Yield
- KPTI N/A
- PMVP N/A
- EPS Growth
- KPTI N/A
- PMVP N/A
- EPS
- KPTI N/A
- PMVP N/A
- Revenue
- KPTI $145,237,000.00
- PMVP N/A
- Revenue This Year
- KPTI $4.37
- PMVP N/A
- Revenue Next Year
- KPTI $19.07
- PMVP N/A
- P/E Ratio
- KPTI N/A
- PMVP N/A
- Revenue Growth
- KPTI N/A
- PMVP N/A
- 52 Week Low
- KPTI $5.90
- PMVP $1.20
- 52 Week High
- KPTI $24.75
- PMVP $2.26
- Technical
- Relative Strength Index (RSI)
- KPTI 43.25
- PMVP 38.72
- Support Level
- KPTI $5.90
- PMVP $1.23
- Resistance Level
- KPTI $8.45
- PMVP $1.40
- Average True Range (ATR)
- KPTI 1.06
- PMVP 0.07
- MACD
- KPTI -0.01
- PMVP -0.01
- Stochastic Oscillator
- KPTI 36.38
- PMVP 24.00
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.